Kenai Therapeutics key facts
- Operator of a biotechnology company intended to cure neurological disease.
- Kenai Therapeutics’s last known valuation is $110.0M.
- It has raised $86.8M; the latest was Early Stage VC ($81.8M) in Jun 2024.
- Notable investors include Euclidean Capital, Alaska Permanent Fund, California Institute for Regenerative Medicine, Cure Ventures, Saisei Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch Kenai Therapeutics: the Monday email on marks, rounds and moves
Kenai Therapeutics funding rounds
No funding rounds for Kenai Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kenai Therapeutics valuation
Kenai Therapeutics's last known valuation is $110 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Kenai Therapeutics investors
6 investors are on record for Kenai Therapeutics, including Euclidean Capital, Alaska Permanent Fund, California Institute for Regenerative Medicine and Cure Ventures.
About Kenai Therapeutics
Operator of a biotechnology company intended to cure neurological disease. The company offers off-the-shelf neuron replacement therapies as potent disease-modifying treatments for neurological disorders, enabling doctors with new-generation approaches for treating diseases like Parkinson's.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 24
- Website
- kenaitx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kenai Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.